Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)

FINANCIAL SERVICES • SHELL COMPANIES • NASDAQ

$10.85

-0.01 (-0.09%)

Market Cap: $263.40M

Last updated: Oct 15, 2026 at 5:00 PM ET

Earnings

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Jun 30, 2026Jun 26 Reported Jun 30, 2026Reported Jun 30	$0.06	N/A	-	N/A	Beat	-	-	-20.0%
Mar 31, 2026Mar 26 Reported Mar 31, 2026Reported Mar 31	$0.06	N/A	-	N/A	Beat	-	-	+16.8%
Dec 31, 2025Dec 25 Reported Dec 31, 2025Reported Dec 31	$0.01	N/A	-	N/A	Beat	-	-	+121.0%
Sep 30, 2025Sep 25 Reported Sep 30, 2025Reported Sep 30	$0.07	N/A	-	N/A	Beat	-	-	-
Jun 30, 2025Jun 25 Reported Aug 14, 2025Reported Aug 14	$0.07	N/A	-	N/A	Beat	-	-	-
Mar 31, 2025Mar 25 Reported May 20, 2025Reported May 20	$0.05	N/A	-	N/A	Beat	-	-	-
Dec 31, 2024Dec 24 Reported Mar 31, 2025Reported Mar 31	$-0.03	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	58.36	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	0.00%	ROIC	29.48%
Financial Health
Debt/Equity	-0.05x	Interest Coverage	N/A
Current Ratio	0.02x	Quick Ratio	0.02x
Trading Statistics
Beta	N/A	Avg Volume	5.99K
52-Week High	$10.89	52-Week Low	$10.29

Technical Indicators Dashboard

Moving Averages

SMA 10$10.86

SMA 20$10.86

SMA 50$10.80

SMA 200$10.60

EMA 10$10.86

EMA 20$10.85

EMA 50$10.81

EMA 200$10.62

MACD

Line: 0.02Signal: 0.02Hist: -0.01

ADX

ADX: 22.3+DI: 25.4-DI: 44.9

Aroon & PSAR

Aroon Up72.0

Aroon DownN/A

PSAR$10.88

Bollinger Bands

Upper Band$10.90

Lower Band$10.83

%B Position69%(Middle)

Band Width0.33

RSI (14-Day)

Neutral

54.1

Momentum Oscillators

Stoch %K52.4

Stoch %D54.0

Williams %R-57.1

ROC (10d)-0.4%

Momentum-0.04

CCI (20d)-28.9

MFI (14d)50.4

Volatility Measures

ATR (14d)$0.01(0.1%)

StdDev (20d)0.02

Hist Vol2.3%(Low)

Volume Flow

VWAP$10.85

OBV8.5M

AD Line7.5M

CMF (20d)0.468

Volume Metrics

Avg Vol (20d)6.4K

Vol Ratio1.2x

VWMA (20d)$10.85

Pivot Points

R3$10.86

R2$10.86

R1$10.86

Pivot Point$10.86

S1$10.86

S2$10.86

S3$10.86

Advanced Oscillators

TSI29.18

Ultimate Osc57.2

KST6.90

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024
Total Revenue	$0	$0	$0	$0	$0	$0	N/A	$0	N/A
Cost of Revenue	$0	$0	N/A	$0	$0	$0	N/A	$0	N/A
Gross Profit	$0	$0	N/A	$0	$0	$0	N/A	$0	N/A

Operating Expenses	$136,934	$143,301	$2.09M	$263,703	$131,919	$330,925	N/A	$144,928	N/A
R&D	$0	$0	$0	$0	$0	$0	$0	$0	$0
SG&A	$136,934	$143,301	$2.09M	$263,703	$131,919	$330,925	$0	$144,928	$0
Operating Income	$-136,934	$-143,301	$-2,089,466	$-263,703	$-131,919	$-330,925	$-279	$-144,928	N/A

Interest Income	$1.86M	$2.11M	$2.30M	$2.45M	$2.42M	$1.59M	$0	$0	$0
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$1.73M	$1.97M	$212,958	$2.18M	$2.29M	$1.25M	$-279	$-144,928	$0
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$1.73M	$1.97M	$212,958	$2.18M	$2.29M	$1.25M	$-279	$-144,928	N/A

EBITDA	$-136,934	$-143,301	$-2,089,466	$-263,703	$-131,919	$-330,925	$-79,986	$-144,928	$-54,931
EBIT	$-136,934	$-143,301	$-2,089,466	$-263,703	$-131,919	$-330,925	N/A	$-144,928	N/A

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about DMAA

News

Drugs Made In America Acquisition (NASDAQ:DMAA) Shares Climb 0.1% - Time to Buy?

Drugs Made In America Acquisition (DMAA) shares saw a modest 0.1% increase, trading at approximately $10.86, though trading volume was significantly lower than average. Despite some institutional investors expanding...

MarketBeat•Oct 9, 2026 2:12 AM ET10/9/26•Somewhat-Bearish

Drugs Made In America Acquisition (DMAA) Stock Price, News & Analysis

This article provides an overview of Drugs Made In America Acquisition (DMAA), a blank check company incorporated in the Cayman Islands and listed on NASDAQ. It details the company's corporate structure...

Stock Titan•Oct 8, 2026 3:41 AM ET10/8/26•Neutral

Drugs Made In America Acquisition (NASDAQ:DMAA) Shares Up 0.1% - Here's What Happened

Drugs Made In America Acquisition (NASDAQ:DMAA) shares increased by 0.1% to $10.84 on Tuesday, despite trading volume being 97% below average. The company, a SPAC focused on pharmaceutical and healthcare mergers...

MarketBeat•Sep 16, 2026 2:01 AM ET9/16/26•Neutral

Drugs Made In America Acquisition Corp. Revenue Breakdown – BOATS:DMAAU

This article provides a financial overview of Drugs Made In America Acquisition Corp. (DMAAU) as presented on TradingView. It indicates that the market is closed for this stock with no recent trades. The page offers...

TradingView•Aug 4, 2026 7:14 PM ET8/4/26•Neutral

Drugs Made In America Acquisition Corp. Revenue Breakdown – BOATS:DMAAR

This page provides financial data and an overview for Drugs Made In America Acquisition Corp. (DMAAR) on TradingView. It indicates that the market is closed, with no current trades. Users can find fundamentals...

TradingView•Aug 3, 2026 12:11 PM ET8/3/26•Neutral

DMAA Valuation and Fair Value

P/E: 58.4x
P/B: -45.1x

See GNG's fair value

DMAA Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROIC: 29.5%
ROE: 0.0%

DMAA Competitors

Company	Ticker
LCNB Corporation	LCNB
First National Corp	FXNC
Kingstone Companies Inc	KINS
FACT II Acquisition Corp.	FACT
Runway Growth Finance Corp	RWAY
Loandepot Inc	LDI
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share	OACC
RiverNorth Managed Duration Municipal Income Fund Inc	RMM

Sector: Financial Services

DMAA Bull Case vs Bear Case

Bull case

DMAA earns a 29.5% return on invested capital.

Bear case

DMAA trades at 58.4x trailing earnings.

Frequently Asked Questions About DMAA

Does DMAA pay dividends?

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) does not currently pay a regular dividend.

What is DMAA's P/E ratio?

Drugs Made In America Acquisition Corp. Ordinary Shares has a price-to-earnings (P/E) ratio of 58.36.

What is DMAA's market cap?

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a market capitalization of $263.40M with a current stock price of $10.85.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In